Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Accounts Payables (2016 - 2023)

Historic Accounts Payables for Aptevo Therapeutics (APVO) over the last 9 years, with Q3 2023 value amounting to $4.0 million.

  • Aptevo Therapeutics' Accounts Payables rose 2334.26% to $4.0 million in Q3 2023 from the same period last year, while for Sep 2023 it was $4.0 million, marking a year-over-year increase of 2334.26%. This contributed to the annual value of $3.5 million for FY2022, which is 106.87% up from last year.
  • As of Q3 2023, Aptevo Therapeutics' Accounts Payables stood at $4.0 million, which was up 2334.26% from $4.9 million recorded in Q2 2023.
  • In the past 5 years, Aptevo Therapeutics' Accounts Payables ranged from a high of $12.1 million in Q3 2019 and a low of $3.2 million during Q3 2022
  • Its 5-year average for Accounts Payables is $5.5 million, with a median of $4.7 million in 2020.
  • In the last 5 years, Aptevo Therapeutics' Accounts Payables soared by 5204.46% in 2019 and then crashed by 6760.54% in 2020.
  • Over the past 5 years, Aptevo Therapeutics' Accounts Payables (Quarter) stood at $6.4 million in 2019, then decreased by 13.15% to $5.6 million in 2020, then tumbled by 37.99% to $3.5 million in 2021, then rose by 1.07% to $3.5 million in 2022, then grew by 14.32% to $4.0 million in 2023.
  • Its Accounts Payables stands at $4.0 million for Q3 2023, versus $4.9 million for Q2 2023 and $4.1 million for Q1 2023.